AMRN
Amarin Corporation plc
AMRN offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over AMRN overall, supported by stronger modeled upside and lower modeled downside.
AMRN Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Under pressure | |
| Strong | |
| Unavailable |
AMRN's cash flow is currently strong, but its revenue and profitability are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
AMRN PE Valuation
AMRN has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
AMRN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Decline | |
| Weakening | |
| Limited | |
| High |
Analysts expect AMRN's losses to grow, with revenue declining.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
UNH has the edge over AMRN on the outlook, with more favorable earnings and revenue expectations.
AMRN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.05 | +$3.20 |
| Q2 2026 | -$0.07 | +$4.36 |
| Q1 2026 | -$0.08 | +$4.32 |
| Q4 2025 | -$0.85 | +$3.15 |
| Q3 2025 | -$3.25 | -$1.25 |
| Q2 2025 | -$4.43 | -$2.63 |
| Q1 2025 | -$4.40 | -$1.80 |
| Q4 2024 | -$4.00 | -$1.00 |
AMRN is still losing money, but far less than before: $0.05 per share over the past year, against $5.36 at its worst in late 2022.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over AMRN on earnings quality, reporting a profit while its opponent remains loss making.
AMRN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $39.6M | -20% |
| Q2 2026 | $42.2M | -42% |
| Q1 2026 | $45.1M | +7.4% |
| Q4 2025 | $49.2M | -21% |
| Q3 2025 | $49.7M | +17% |
| Q2 2025 | $72.7M | +7.8% |
| Q1 2025 | $42M | -26% |
| Q4 2024 | $62.3M | -17% |
AMRN's revenue has slid since its 2020 peak: $40M last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -6% | +16 points |
| Q2 2026 | -28% | -6.5 points |
| Q1 2026 | -25% | +15 points |
| Q4 2025 | -13% | +72 points |
| Q3 2025 | -22% | +37 points |
| Q2 2025 | -22% | -21 points |
| Q1 2025 | -40% | -16 points |
| Q4 2024 | -84% | -78 points |
AMRN's operating margin was −6% last quarter, up 16 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over AMRN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over AMRN on profitability, with a higher operating margin.
AMRN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $9.2M | +$21.9M |
| Q2 2026 | $6.6M | -60% |
| Q1 2026 | $6.4M | +$18.8M |
| Q4 2025 | $15.3M | +$28.6M |
| Q3 2025 | -$12.7M | -$10.3M |
| Q2 2025 | $16.6M | +$19.4M |
| Q1 2025 | -$12.5M | +$142K |
| Q4 2024 | -$13.3M | -$12.7M |
AMRN's free cash flow has turned positive after two years mostly in the red: $37M over the past year.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH still generates free cash flow, though less than at its 2022 peak: $22.8B over the past year.
AMRN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.7% | +11.4M shares |
| 1 year | +3% | +12.3M shares |
| 3 years | +1995% | +407M shares |
| 5 years | +2058% | +408M shares |
| Available history | +2398% | +411M shares |
AMRN has 428M diluted shares, up 3% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over AMRN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
AMRN Net Leverage
AMRN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
AMRN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.1 | Neutral |
| Stochastic | 13.7 | Oversold |
AMRN's weekly RSI is 36 (neutral) and its Stochastic is 14 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
AMRN PE vs Healthcare Sector
AMRN has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
AMRN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.0 | 2.8% below |
| 20 week MA | $13.3 | 12% below |
| 50 week MA | $14.2 | 18% below |
| 100 week MA | $13.7 | 15% below |
| 200 week MA | $16.8 | 31% below |
AMRN is in a downtrend: it's below all five of its weekly moving averages, and 31% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over AMRN on trend strength, trading above more of its moving averages.
AMRN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $431.0 | $100.2 | -77% |
| 2021 | $100.2 | $70.2 | -30% |
| 2022 | $70.2 | $25.0 | -64% |
| 2023 | $25.0 | $17.4 | -30% |
| 2024 | $17.4 | $8.96 | -49% |
| 2025 | $8.96 | $14.1 | +58% |
| 2026 YTD | $14.1 | $11.7 | -17% |
AMRN has finished lower in five of the last six years. It's down 17% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over AMRN on returns for 2026, with the stronger performance.